In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Horizon Pharma Inc (HZNP), with a price target of $25. The company’s shares closed yesterday at $19.35.
Rivkind Koffler observed:
“We reiterate our Buy rating on Krystexxa momentum and upcoming teprotumumab Phase III data (expected 2Q:19).”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 8.1% and a 43.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Horizon Pharma Inc with a $24.78 average price target, implying a 28.1% upside from current levels. In a report issued on October 23, Cowen & Co. also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.25 and a one-year low of $12.55. Currently, Horizon Pharma Inc has an average volume of 1.43M.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.
